Skip to main navigation Skip to search Skip to main content

A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient non-anemic patients with chronic kidney disease

  • King's College Hospital NHS Foundation Trust.
  • King's College London
  • Guy's and St Thomas' NHS Foundation Trust
  • St George's University Hospitals NHS Foundation Trust
  • Hull and East Yorkshire Hospitals NHS Trust
  • College of Life Sciences
  • University of Leicester
  • University Hospitals of Leicester NHS Trust
  • Hope Hospital
  • Salford Royal Hospital Foundation Trust
  • Barts and The London Queen Mary's School of Medicine and Dentistry
  • Royal London Hospital (Barts and the London NHS Trust)
  • Queen Margaret University
  • Epsom and St Helier University Hospitals NHS Trust
  • UCL University College London
  • The George Institute for Global Health, Sydney
  • Department of Mental Health Sciences

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)
165 Downloads (Pure)

Abstract

Introduction: Patients with chronic kidney disease (CKD) are often iron deficient, even when not anemic. This trial evaluated whether iron supplementation enhances exercise capacity of nonanemic patients with CKD who have iron-deficiency. Methods: Prospective, multicenter double-blind randomized controlled trial of nondialysis patients with CKD and iron-deficiency but without anemia (Hemoglobin [Hb] >110 g/l). Patients were assigned 1:1 to intravenous (IV) iron therapy, or placebo. An 8-week exercise program commenced at week 4. The primary outcome was the mean between-group difference in 6-minute walk test (6MWT) at 4 weeks. Secondary outcomes included 6MWT at 12 weeks, transferrin saturation (TSAT), serum ferritin (SF), Hb, renal function, muscle strength, functional capacity, quality of life, and adverse events at baseline, 4 weeks, and at 12 weeks. Mean between-group differences were analyzed using analysis of covariance models. Results: Among 75 randomized patients, mean (SD) age for iron therapy (n = 37) versus placebo (n = 38) was 54 (16) versus 61 (12) years; estimated glomerular filtration rate (eGFR) (34 [12] vs. 35 [11] ml/min per 1.73 m 2], TSAT (23 [12] vs. 21 [6])%; SF (57 [64] vs. 62 [33]) μg/l; Hb (122.4 [9.2] vs. 127 [13.2] g/l); 6MWT (384 [95] vs. 469 [142] meters) at baseline, respectively. No significant mean between-group difference was observed in 6MWT distance at 4 weeks. There were significant increases in SF and TSAT at 4 and 12 weeks (P < 0.02), and Hb at 12 weeks (P = 0.009). There were no between-group differences in other secondary outcomes and no adverse events attributable to iron therapy. Conclusion: This trial did not demonstrate beneficial effects of IV iron therapy on exercise capacity at 4 weeks. A larger study is needed to confirm if IV iron is beneficial in nondialysis patients with CKD who are iron-deficient.

Original languageEnglish
Pages (from-to)1496-1505
Number of pages10
JournalKidney International Reports
Volume8
Issue number8
DOIs
Publication statusPublished - 9 May 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'A randomized trial of intravenous iron supplementation and exercise on exercise capacity in iron-deficient non-anemic patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this